Artificial intelligence in healthcare is moving from theory to real-world impact just as central banks, inflation trends, and energy markets keep broader sentiment on edge. While policy signals from the US Federal Reserve, Bank of England, and others shape funding costs and risk appetite, AI healthcare stocks sit at the intersection of rising data use, pressure to control medical costs, and demand for better outcomes. The Transformative AI Healthcare Stocks screener highlights companies using AI for diagnostics, treatment decisions, and efficiency gains. This article highlights 3 notable stocks from that screener for investors researching this theme further.

Pfizer (PFE)

Overview: Pfizer is a large global biopharmaceutical company that discovers, develops, manufactures, and sells prescription medicines, vaccines, and biosimilars across areas such as internal medicine, oncology, rare diseases, inflammation, and infectious disease.

Operations: Pfizer generates about US$61.9b in revenue primarily from its Global Biopharmaceuticals Business segment, with around US$37.4b coming from the United States and the rest split between developed and emerging markets.

Market Cap: US$148.2b

Pfizer provides exposure to some major themes in healthcare, from obesity drugs and oncology to next generation vaccines, supported by a broad portfolio that includes brands like Eliquis, Ibrance, Prevnar, and Paxlovid. The stock screens as significantly below an estimated cash flow based fair value. However, analysts still expect near term revenue and earnings pressure, low returns on equity, and a dividend that is not well covered by current earnings. At the same time, an expanding late stage pipeline in cancer and obesity, deeper use of AI in R&D, and a growing footprint in emerging markets could eventually change that picture. The tension between those risks and potential rewards is what may make Pfizer worth closer consideration.

Pfizer appears caught between pressure on earnings and an AI powered pipeline that could reset expectations. Before you decide where you stand on the stock, review the 1 key reward and 4 important warning signs (3 are major!)

Tempus AI (TEM)

Overview: Tempus AI is a US based healthcare technology company that uses large scale genomic, clinical, imaging, and real world data, combined with AI tools, to support cancer care, cardiovascular and psychiatric treatment decisions, and drug development for biopharma partners.

Operations: Tempus AI generates about US$1.4b in revenue from Medical Labs & Research services in the United States.

Market Cap: US$9.4b

Tempus AI attracts attention because it sits at the center of AI driven diagnostics and drug development, with FDA cleared tools, an expanding genomic testing menu, and a growing set of biopharma collaborations that rely on its data platforms. The stock trades below one estimate of its future cash flow value and analysts see room for revenue growth, but the company is still loss making, has deeply negative returns on equity and depends heavily on external funding, so the path to sustainable profitability is not yet clear. Recent launches such as the Lens AI platform, FDA cleared ECG and tumor profiling assays, and new open source digital pathology partnerships add to the perceived long term potential; however, they also raise questions about execution risk and future reimbursement.

Tempus AI sits at the crossroads of AI tools, genomic data and biopharma partnerships. Yet the real story may lie in how those pieces fit together in the analysis report for Tempus AI

Medtronic (MDT)

Overview: Medtronic is a global medical device company that provides implantable heart devices, neurostimulation systems, surgical tools, AI powered surgical video and robotics platforms, and diabetes management products to hospitals and clinicians worldwide.

Operations: Medtronic generates about US$31.6b in annual revenue, led by Cardiovascular at US$14.0b, Neuroscience at US$10.3b, Medical Surgical at US$8.8b, and Diabetes at US$3.1b, with a smaller US$0.2b contribution from other activities.

Market Cap: US$103.2b

Medtronic combines chronic disease exposure, AI enabled devices, and a long product history to offer investors a mix of scale and product depth that is difficult to replicate. Potential growth drivers include demand in cardiac ablation, robotics and hypertension therapies, alongside recent deals such as Scientia Vascular and SPR Therapeutics that add to its neurovascular and pain portfolios. A 3.49% dividend and a P/E below peers indicate a valuation that is not implying a flawless outlook. However, margin pressure, underperforming areas in Diabetes, MedSurg and Neuroscience, and ongoing FDA recalls highlight execution and regulatory risk. For investors, the key question is whether Medtronic’s AI powered pipeline and restructuring can ultimately offset those concerns.

Medtronic’s AI devices, restructuring and 3.49% yield hint at a story investors may be only half seeing. The real question is what the 6 key rewards and 1 important warning sign reveals about what comes next.

The three AI healthcare stocks in this article are just the starting point, as the full screener surfaced 37 more companies with equally compelling narratives through the Transformative Artificial intelligence (AI) Healthcare Stocks screener. Use Simply Wall St to identify the specific AI catalysts, risk flags, and fundamental stories that matter most to you, so you can analyze and shortlist your highest conviction ideas more efficiently.

Take Control of Your Investment Journey

If Medtronic or any of these companies have caught your attention, register for FREE with Simply Wall St and add your companies to a Watchlist to monitor the share price against the fair value and track any new developments as they happen. Once you've made your move, manage your holdings with our Portfolio Command Center that filters out the noise to deliver only the most critical, actionable updates. Throughout your journey, our Community allows you to filter the best ideas from thousands of investor perspectives. By uncovering hidden catalysts and risks early, you'll accelerate your decision-making and stay one step ahead of the market.

Seeking Fresh Alternatives Beyond AI Healthcare?

Fresh opportunities move quickly, and once momentum builds, ideal entry ranges can slip away before the crowd notices. Scan these curated stock ideas while it still matters, act now.

• Spot resilient compounders before momentum takes off by reviewing the curated list of solid balance sheet and fundamentals (48 results) that filters for companies with stronger finances than the broader market.
• Ride potential income and price swings together by scanning the hand picked 9 dividend fortresses built for investors who want yield with sturdier fundamentals.
• Get ahead of the next infrastructure breakout by checking the focused 34 power grid technology and infrastructure stocks featuring companies tied to long term grid and electrification projects.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.